Navigation Links
AVANIR Pharmaceuticals To participate in two conferences in March
Date:3/1/2013

ALISO VIEJO, Calif., March 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

  • Cowen & Company 33rd Annual Healthcare Conference
    • Location: Boston Marriott Copley Place, Boston, MA
    • Presentation date: Tuesday March 5, 2013
    • Presentation time: 9:20 a.m. E.T.
  • 25th Annual ROTH Conference
    • Location: Ritz-Carlton, Laguna Niguel, CA
    • Presentation date: Wednesday March 20, 2013
    • Presentation time: 11:30 a.m. P.T.

A live webcast and 30-day archive of these presentations will be available at http://ir.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements , PhD
ir@avanir.com
+1 (949) 389-6700


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
2. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... PRM, a chronic disease and transitions of care solution for use by healthcare ... to work at the top of their license. Care teams, care managers ...
(Date:1/24/2017)... DURHAM, N.C. , Jan. 24, 2017 ... service and technology, announces that Daniel Eisenman , ... Biosafety Officer. In his new role, ... and manage a forthcoming institutional biosafety committee (IBC) service. ... navigating the IBC landscape. The new IBC service represents ...
(Date:1/24/2017)... 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... to increase the size of the offering by 75% and ... with warrants to purchase 1,842,106 shares of common stock of ... of common stock (the "Exercise Price"), at a price to ... "Public Price"). The warrants have a term of four (4) ...
(Date:1/24/2017)... USA & Geneva, Switerland (PRWEB) , ... January ... ... to announce the first commercially available malaria Plasmodium falciparum culture panels with standard ... falciparum culture panels, which are available in a range of concentrations from six ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):